David Chin is an Associate Director with the Life Science Practice at Navigant. His professional experience spans both medical device and pharma/biotech, as a commercial operations leader in Fortune 500 and start-ups. Prior to joining Navigant, David was a Senior Director, Commercial Operations for Baxano Surgical, a spine company where he was responsible for managing all commercial processes and infrastructure to support operations of the sales force and distributors.
Previous to this, David was Senior Director Operations for Stryker Orthopaedics (OtisMed Business Unit), where he was responsible for the entire order-to-ship operations of the companies’ flagship product ShapeMatch Cutting Guides, custom designed patient specific instrument for knee replacement. David was part of the founding team at OtisMed (whic h Stryker acquired) that built the company from inception to completing over 23,000 knee replacements and successful exit in three years. David has extensive knowledge and understanding of the drivers and issues that affect the provider, payer and patient in today’s changing healthcare environment, having held positions in reimbursement at Lash Group and Elan; an oncology pharmacist at Toronto General Hospital and equity research at BMO Capital Markets.
David holds a B.Sc. in Pharmacy from the University of Toronto, Faculty of Pharmacy and an MBA from the Schulich School of Business, York University (Canada). He is a Registered Pharmacy (Ontario) and a Chartered Financial Analyst (CFA).